Cellyan Biotechnology
HKPD
4 hedge funds and large institutions have $60.7K invested in Cellyan Biotechnology in 2025 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 0 closing their positions.
241% more capital invested
Capital invested by funds: $17.8K → $60.7K (+$42.9K)
100% more funds holding
Funds holding: 2 → 4 (+2)
0.56% more ownership
Funds ownership: 0.11% → 0.67% (+0.56%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SG
StoneX Group
New York
|
+$46.4K |
| 2 |
Two Sigma Investments
New York
|
+$18K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$1.54K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SG
1
StoneX Group
New York
| $35.7K | +$46.4K | +43,284 | New |
|
|
2
Two Sigma Investments
New York
| $13.8K | +$18K | +16,751 | New |
|
|
CS
3
Clear Street
New York
| $9.91K | – | – | – |
|
|
4
UBS Group
Zurich,
Switzerland
| $1.27K | +$1.54K | +1,438 | +1,467% |
|
HKPD Hedge Fund Activity: Q4 2025 in Review
4 of the 8,238 institutional investors tracked by Wall St. Rank reported a position in Cellyan Biotechnology (HKPD) for Q4 2025, worth a combined $60.7K — up 241% from $17.8K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new HKPD positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was StoneX Group, opening a new position worth an estimated $46.4K.
- 4 institutional investors held Cellyan Biotechnology (HKPD) as of Q4 2025, up from 2 in Q3 2025.
- Funds reported $60.7K of Cellyan Biotechnology stock for Q4 2025, up 241% quarter-over-quarter.
- 2 funds opened new Cellyan Biotechnology positions in Q4 2025 and 0 closed out, a net change of +2 holders.
- The largest Cellyan Biotechnology buyer in Q4 2025 was StoneX Group, an estimated $46.4K added.
Based on aggregated 13F filings for Q4 2025.